Federal Register Notice: FDA has determined the regulatory review period for SyntheMed, Inc.’s Repel-CV is 4,023 days for extending a patent which claims the medical device. It is a bioresorbable adhesion barrier indicated for reducing the severity of post-operative cardiac adhesions in pediatric patients who are likely to require reoperation via sternotomy. To view this notice, click here.
